Drug intelligence / Profile preview

VGT-1849A

Development stage: Unknown
Lead developer: Vanda Pharmaceuticals
Modality: Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics

Overview

VGT-1849A is an antisense oligonucleotide (ASO) molecule developed jointly by Vanda Pharmaceuticals and OliPass Corporation. It is based on OliPass’ proprietary modified peptide nucleic acids. Vanda Pharmaceuticals entered into an agreement with OliPass in September 2022 for its joint development, funding the research and development activities, and holding an option to license the jointly developed intellectual property.

Targets

JAK2 (Janus kinase 2)

Beyond the preview

Go deeper on VGT-1849A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VGT-1849A.

Explore the full profile